LOW EXPRESSION OF NIBRIN PREDICTS BETTER PROGNOSIS IN PATIENTS WITH OVARIAN CANCER TREATED WITH TRABECTEDIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD)

被引：0
|
作者：
Aracil, M. [1 ]
Nieto, A. [1 ]
Tanovic, A. [2 ]
Monk, B. J. [3 ]
Kaye, S. B. [4 ]
Poveda, A. [5 ]
Herzog, T. J. [6 ]
Parekh, T. [7 ]
Badri, N. [2 ]
Galmarini, C. M. [1 ]
机构：
[1] PharmaMar, Dept Res & Dev, Madrid, Spain
[2] PharmaMar, Med Affairs, Madrid, Spain
[3] St Josephs Hosp, Creighton Univ Sch Med, Div Gynecol Oncol, Phoenix, AZ USA
[4] Royal Marsden Hosp, Dept Canc Med, Sutton, Surrey, England
[5] Valencian Inst Oncol, Dept Gynecol Oncol, Valencia, Spain
[6] Columbia Univ Coll Phys & Surg, Div Gynecol Oncol, New York, NY 10032 USA
[7] Janssen LLC, Dept Res & Dev, Raritan, NJ USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2013年 / 23卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [11] An observational, multicenter, prospective study of trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC)
    Reichert, D.
    Wimberger, P.
    Ringsdorf, U.
    Krohn, M.
    Runnebaum, I.
    ANNALS OF ONCOLOGY, 2017, 28
  • [12] Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors
    Villanucci, Alessandro
    Tavella, Ketty
    Vannini, Laura
    Rossi, Virginia
    Nobili, Stefania
    Amunni, Gianni
    Mazzei, Teresita
    Mini, Enrico
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (06) : 635 - 639
  • [13] Pembrolizumab plus pegylated liposomal Doxorubicin for Patients with Ovarian Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (01) : 19 - 20
  • [14] A RANDOMIZED PHASE III STUDY OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) VERSUS PLD IN RELAPSED, RECURRENT OVARIAN CANCER (OC)
    Monk, B. J.
    Herzog, T.
    Kaye, S.
    Krasner, C. N.
    Vermorken, J.
    Muggia, F.
    Pujade-Lourraine, E.
    Renshaw, F. G.
    Lebedinsky, C.
    Poveda, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 2 - 2
  • [15] The daily practice use of trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) across Germany
    Runnebaum, I. B.
    Reichert, D.
    Ringsdorf, U.
    Hesse, T.
    Kuther, M.
    Sehouli, J.
    Wimberger, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 193 - 193
  • [16] Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older
    Vergote, I.
    Vermorken, J.
    Pujade-Lauraine, E.
    Monk, B.
    Lisyanskaya, A.
    Rolski, J.
    Vasanthan, S.
    Santabarbara, P.
    Bayever, E.
    Poveda, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 458 - 458
  • [17] Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer
    Lorusso, D
    Ferrandina, G
    Lo Voi, R
    Fagotti, A
    Scambia, G
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 98 - 103
  • [18] When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
    Colombo, Nicoletta
    FUTURE ONCOLOGY, 2017, 13 (23) : 23 - 29
  • [19] Pegylated liposomal doxorubicin (PLD) in heavily pretreated epithelial ovarian cancer patients
    Gorumlu, Gurbuz
    Kucukzeybek, Yuksel
    Karabulut, Bulent
    Terek, Mustafa C.
    Uslu, Ruchan
    Sanli, Ulus A.
    Akman, Levent
    Ozsaran, Aydin
    Dikmen, Yilmaz
    Goker, Erdem
    ANNALS OF ONCOLOGY, 2006, 17 : 172 - 172
  • [20] Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in patients with intermediate sensitive relapsing advanced ovarian cancer
    Stuart, G.
    Oza, A.
    Provencher, D.
    Bentley, J.
    Plante, M.
    Lotocki, R.
    Power, P.
    Miller, D.
    Ghatage, P.
    Pouliot, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 272 - 272
12345